Back

Cardiac reverse remodeling in the trial of accelerated guideline-directed medical therapy for Heart Failure (TEAM-HF)

11 May 2024 (08:00 - 20:00)
Organised by: Logo
Congress Presentation Part of: Late breaking clinical trials II Pharmacotherapy HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Laura Cohen

Massachusetts General Hospital - Harvard Medical School, Boston (United States of America)

9 More presentations in this session

Presentation thumbnail
Transendocardial injection of autologous expanded CD34+ Stem Cells (ProtheraCytes) promotes reverse cardiac remodeling in patients with left ventricular dysfunction after acute myocardial infarction
Professor F. Zannad (Vandoeuvre-Les-Nancy, FR)
Slides Video
Presentation thumbnail
Discussant review - EXCELLENT
Professor F. Gustafsson (Pleasanton, US)
Slides Video
Presentation thumbnail
Bio-ADM as a marker for residual congestion and early rehospitalization in patients hospitalized for acute heart failure; data from STRONG-HF
Mr G. Voordes (Groningen, NL)
Slides Video
Presentation thumbnail
Discussant review - STRONG-HF
Professor A. Bayes Genis (Badalona, ES)
Slides Video
Presentation thumbnail
Semaglutide and cardiovascular outcomes in patients with overweight or obesity and heart failure: A pre-specified analysis from the SELECT trial
Professor J. Deanfield (London, GB)
Slides Video

Access the full session

Session thumbnail
Late breaking clinical trials II
Video

The Event

Event poster

Heart Failure 2024

11 May - 14 May 2024
You may be interested in
thumbnail
Congress Presentation
Discussant review - TEAM-HF: Cardiac Reverse Remodeling After Accelerated Implementation of Guideline-Directed Medical Heart Failure Therapy in a General Cardiology Clinic
thumbnail
Congress Presentation
First implementation results from the Trial for Evaluating Accelerated Guideline-Directed Medical Therapy for Heart Failure
thumbnail
Congress Presentation
Relationship between left ventricular reverse remodeling and guideline-directed medical therapy intensity in de novo heart failure with reduced ejection fraction patients: insight from TRANS-HF trial

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources